Lisocabtagene maraleucel

Phase 2Cell therapy

Lisocabtagene maraleucel is a cell therapy that works as a CD19 CAR-T.[2] It is being investigated across 7 indications, with its most advanced program in Phase 2.[1]

Lisocabtagene maraleucel is one of 145 cell therapy programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

144

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Mantle Cell LymphomaActive, not recruiting

Follicular LymphomaActive, not recruiting

Recurrent Diffuse Large B-Cell LymphomaRecruiting

Diffuse Large B-Cell LymphomaRecruiting

Richter's TransformationRecruiting

Richter's SyndromeRecruiting

LymphomaPhase 2

Active, not recruiting

Mantle Cell LymphomaPreclinical

Active, not recruiting

Follicular LymphomaPreclinical

Active, not recruiting

Recurrent Diffuse Large B-Cell LymphomaPreclinical

Recruiting

Diffuse Large B-Cell LymphomaPhase 2

Recruiting

Richter's TransformationPhase 2

Recruiting

Richter's SyndromePhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Lisocabtagene maraleucel

Bristol-Myers Squibb

Phase 2

4 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Richter's Syndrome

NCT05873712

Q1 2029

Phase 2Active, not recruiting

Lymphoma

NCT05583149

Q4 2029

Phase 2Recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

NCT07194980

Q2 2030

Phase 2Recruiting

Diffuse Large B-Cell Lymphoma

NCT05633615

Clinical

Trials by Indication[1]

Lymphoma4 trials

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT05359211·27 enrolled

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Active, not recruiting·PPatrick C. Johnson, MD·Phase 2·NCT05583149·28 enrolled

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03744676·104 enrolled

Show 1 more trial

Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

Not yet recruiting·MMassachusetts General Hospital·Phase 2·NCT07711483·56 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma2 trials

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company··NCT06788639·300 enrolled

Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT07194980·20 enrolled

Cell Therapy1 trial

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06357754·50 enrolled

Richter's Syndrome1 trial

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recruiting·AAseel Alsouqi·Phase 2·NCT05873712·24 enrolled

CAR-T1 trial

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Suspended·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT04855253·30 enrolled

9 more indications

Richter's Transformation1 trial

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recruiting·—·Phase 2·NCT05672173·20 enrolled

Recruiting·SSWOG Cancer Research Network·Phase 2·NCT05633615·396 enrolled

Second-line Therapy1 trial

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03483103·74 enrolled

Recurrent Diffuse Large B-Cell Lymphoma1 trial

A Phase 1/2 Open-Label Study Evaluating the Safety and Efficacy of ST-067 in Combination With CD19-Directed CAR T-Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Suspended·FFred Hutchinson Cancer Center·Preclinical·NCT07098364·33 enrolled

Marginal Zone Lymphoma1 trial

Non-interventional Cohort Study of Patients Treated With Liso-Cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Marginal Zone Lymphoma in the Postmarketing Setting

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07777120·300 enrolled

Refractory Diffuse Large B-Cell Lymphoma1 trial

A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Completed·NNeoImmuneTech·Phase 1·NCT05075603·17 enrolled

Large B-cell Lymphoma1 trial

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

Recruiting·LLyell Immunopharma, Inc.·Phase 3·NCT07188558·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Lisocabtagene maraleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lisocabtagene maraleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lisocabtagene maraleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 1 publication indexed for Lisocabtagene maraleucel. U.S. National Library of Medicine.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CD19 CAR-T[2]
Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

Key Publications[4]

Liso-cel in Second-Line LBCL: TRANSFORM Phase 3

LancetJun 16, 2022DOI: 10.1016/S0140-6736(22)00862-X

Lisocabtagene maraleucel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2029

Q4 2029

Q2 2030

Trials by Indication[1]

Lymphoma4 trials

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma2 trials

Cell Therapy1 trial

Richter's Syndrome1 trial

CAR-T1 trial

Richter's Transformation1 trial

Mantle Cell Lymphoma1 trial

Follicular Lymphoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Second-line Therapy1 trial

Recurrent Diffuse Large B-Cell Lymphoma1 trial

Marginal Zone Lymphoma1 trial

Refractory Diffuse Large B-Cell Lymphoma1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News